Return to homepagePandemic Pact

MRNA VACCINE DEVELOPMENT

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 75N93024C00014-0-9999-1

Grant search

Key facts

  • Disease

    Influenza caused by Influenza A virus subtype H1

  • Start & end year

    2024
    2026

  • Known Financial Commitments (USD)

    $594,566

  • Funder

    National Institutes of Health (NIH)

  • Principal Investigator

    KATERINA ANDRIANOVA

  • Research Location

    United States of America

  • Lead Research Institution

    FLAG BIO, INC.

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Vaccine design and administration

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The contractor will develop mRNAFlag as a vaccine adjuvant. mRNAFlag is an mRNA transcript that encodes for the deimmunized TLR5 agonist GP532. mRNAFlag would be developed within the context of an influenza mRNA vaccine, using an A/California/07/2009(H1N1) hemagglutinin in an LNP formulation used by Moderna for its SARS-CoV-2 vaccine.